Re-post: Cancer treatment myths: Any truth to these common beliefs? - MayoClinic.com

Blogger Buzz: Blogger is back

May 13, 2011

Blogger is back

What a frustrating day. We’re very sorry that you’ve been unable to publish to Blogger for the past 20.5 hours. We’re nearly back to normal — you can publish again, and in the coming hours posts and comments that were temporarily removed should be restored. Thank you for your patience while we fix this situation. We use Blogger for our own blogs, so we’ve also felt your pain.

Here’s what happened: during scheduled maintenance work Wednesday night, we experienced some data corruption that impacted Blogger’s behavior. Since then, bloggers and readers may have experienced a variety of anomalies including intermittent outages, disappearing posts, and arriving at unintended blogs or error pages. A small subset of Blogger users (we estimate 0.16%) may have encountered additional problems specific to their accounts. Yesterday we returned Blogger to a pre-maintenance state and placed the service in read-only mode while we worked on restoring all content: that’s why you haven’t been able to publish. We rolled back to a version of Blogger as of Wednesday May 11th, so your posts since then were temporarily removed. Those are the posts that we’re in the progress of restoring.

Again, we are very sorry for the impact to our authors and readers. We try hard to ensure Blogger is always available for you to share your thoughts and opinions with the world, and we’ll do our best to prevent this from happening again.

financial: Shortage of Radioisotopes Threatens Medical Research and Treatment

Pharma: Pain Therapeutics - SMi Group - Event Details - UK - Overview

This conference seeks to address Recent successes and failures for new drugs in development Translational pain R&D Current human and animal pain models Pain managment methodologies Pain treatment Clinical trial design considerations

WORD of HOPE Podcast | Ovarian Cancer News, Research and Information

WORD of HOPE Partners

• 
• 

abstract: Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.

OBJECTIVES:

To evaluate in a large phase III recurrent ovarian cancer trial (OVA-301): 1) the concordance between CA-125 level vs. best overall response (OR) and progression-free survival (PFS) determined by radiological assessment 2) the impact of early CA-125 changes over the subsequent radiological response, and 3) the prognostic value of CA-125 response and CA-125 PFS to predict radiological response and PFS.

just reported: Blogger begins restoring posts as outage continues - Faster Forward - The Washington Post